23 articles
GLP-1 weight loss drugs may boost athletic performance beyond shedding pounds, but scientists warn the evidence in elite athletes simply isn't there yet.
Tirzepatide may cut heart attack risk by 33% in people with type 2 diabetes and heart disease, a major BMJ study of 53,000 patients found.
Mounjaro leads weight-loss drugs with 14.9% more loss than lifestyle alone, but it also causes the most muscle loss at 8.3%.
VA coverage for weight-loss drugs depends on your diagnosis, not just obesity; knowing which conditions qualify before your appointment changes everything.
GLP-1 weight loss drugs like Wegovy and Zepbound can shed up to 21% of body weight, but meaningful results take 6 to 12 months.
Obesity drugs can slash body weight by up to 15%, yet most show no meaningful quality-of-life gains, making individual risk assessment essential.
Wegovy pill is now available in UK pharmacies as a private prescription, offering a needle-free semaglutide option from £69 per month.
Medicare's new $50/month weight-loss drug program launches July 1, offering GLP-1 medications to 3.8 million eligible seniors, but doctors urge caution on.
GLP-1 drugs like semaglutide cause up to 45% muscle loss with weight, but protein targets and resistance training can largely prevent it.
Intermittent fasting matches calorie counting for weight loss but offers a key bonus: people think about food far less, new research finds.
Setting a weight loss goal before starting Zepbound led to significantly better results, a study of 81,000 people found.
Retatrutide, a new weight-loss drug, helped trial participants lose 30% of their body weight, surpassing Ozempic and matching bariatric surgery results.
People taking Ozempic and Wegovy are walking 560 fewer steps daily after starting treatment, and experts say exercise must be part of any weight loss drug.
GLP-1 drugs like Zepbound now treat sleep apnea by targeting weight loss, with patients reducing breathing interruptions by up to 50%.
The American Medical Association adopts new policies to eliminate insurance barriers blocking patient access to weight-loss drugs like Ozempic.
New oral medication helps menopausal women lose up to 30 pounds in 72 weeks, with consistent weight loss results across all menopause stages.
New dual-action weight loss drug survodutide helped people lose 12% body weight while clearing dangerous liver fat in 84% of users.
About 15% of GLP-1 users are microdosing to cut costs and reduce side effects, but doctors warn there's no safety data on this approach.
Researchers created an experimental fat-burning pill that preserves muscle mass unlike Ozempic, targeting metabolism directly in early trials.
New research reveals 26% of people with normal BMI actually meet clinical obesity criteria, suggesting millions miss needed health screenings.
Scientists discover fat cells have a dual role beyond energy storage, potentially revolutionizing obesity treatment by focusing on cell health.
Semaglutide shows promise treating MASH, a silent liver disease affecting 250 million people, by reducing inflammation and reversing scarring.
Lower tirzepatide doses maintain weight loss long-term, with 5mg keeping off 16.6% body weight vs 9.9% for those who stopped treatment entirely.
